A phase 2, multicenter, open label, randomized trial of AMG 706 [motesanib] or bevacizumab in combination with paclitaxel and carboplatin for advanced non-squamous non-small cell lung cancer.

Trial Profile

A phase 2, multicenter, open label, randomized trial of AMG 706 [motesanib] or bevacizumab in combination with paclitaxel and carboplatin for advanced non-squamous non-small cell lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Motesanib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 13 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClincialTrials.gov.
    • 25 Aug 2011 New source identified and integrated (Clinical Trial Registry - India; CTRI2007-091-000017).
    • 01 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top